[en] BACKGROUND AND AIMS: Patients with inflammatory bowel disease have an increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD). The study aims to determine the prevalence of CVD and VTE risk factors in a large population of patients with ulcerative colitis (UC). METHODS: We conducted a cross-sectional study in 33 French and Belgium referral centers. A questionnaire was developed to explore self-reported risk factors for VTE and CVD, based on the latest international guidelines, in consecutive patients with UC. RESULTS: A total of 1071 patients with UC were included. There were 539 women (50.3%), and the median age of patients was 44 years [32; 57]. The median disease duration was 10 years [6; 17]. In the cohort, 36.5% of patients reported no cardiovascular risk factor (CVRF) and 72% had ≤ 1 CVRF. Regarding cardiovascular risk markers (CVRM) 36.9% of patients reported no CVRM and 78% had ≤ 1 CVRM. Of the 1071 patients, 91.3% of patients reported no VTE strong risk factor and 96% had ≤ 1 VTE moderate risk factor. CONCLUSION: This is the first cohort specifically designed to assess both VTE and CVD risks in patients with UC. More than one third of patients with UC had no CVRF and around three quarters had ≤ 1 CVRF. In addition, more than nine out of ten patients had no VTE strong risk factor and ≤ 1 moderate risk factor. Physicians should be aware of these factors in their patients.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Guillo, Lucas ; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Chemin des Bourrely, 13015, Marseille, France. lucas.guillo690@gmail.com.
Amiot, Aurélien; Department of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP, EC2M3-EA7375, University of Paris Est Créteil, Créteil, France.
Serrero, Mélanie; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Chemin des Bourrely, 13015, Marseille, France.
Altwegg, Romain; Department of Gastroenterology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.
Roblin, Xavier; Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Étienne, France.
Atanasiu, Calina; Department of Gastroenterology, AP-HP, Hôpital Saint-Joseph, Paris, France.
Buisson, Anthony; Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
Le Berre, Catherine; Department of Gastroenterology, Institut des Maladies de L'Appareil Digestif (IMAD), CIC Inserm 1413, Nantes University Hospital, Nantes, France.
Reenaers, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Gornet, Jean-Marc; Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, Université de Paris, Paris, France.
Laharie, David; CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, 33000, Bordeaux, France.
Abitbol, Vered; Department of Gastroenterology, Paris Descartes University, Sorbonne Paris Cité, Cochin Hospital, APHP, Paris, France.
Biron, Amélie; Department of Gastroenterology, Reims University Hospital, Reims, France.
Caron, Bénédicte; Department of Gastroenterology, Hautepierre Strasbourg University Hospital and INSERM U1113 IRFAC, University of Strasbourg, Strasbourg, France.
Nancey, Stéphane; Department of Gastroenterology and Inserm U1111-CIRI, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
Chupin, Antoine; Department of Gastroenterology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris and Université Paris Saclay, Le Kremlin-Bicêtre, France.
Blain, Antoine; Department of Gastroenterology, Institut Mutualiste Montsouris, Paris, France.
Vuitton, Lucine; Department of Gastroenterology, Besancon University Hospital, Besançon, France.
Caillo, Ludovic; Department of Gastroenterology, University Hospital of Nimes, Nîmes, France.
Kirchgesner, Julien; Department of Gastroenterology, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Sorbonne Université, Paris, France.
Nachury, Maria; Univ, Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
Peyrin-Biroulet, Laurent; Department of Gastroenterology, Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Roda G, Chien Ng S, Kotze PG et al. Crohn’s disease. Nat Rev Dis Primer 2020;6:22. DOI: 10.1038/s41572-020-0156-2
Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet 2017;389:1756–1770. DOI: 10.1016/S0140-6736(16)32126-2
Harbord M, Annese V, Vavricka SR et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239–254. DOI: 10.1093/ecco-jcc/jjv213
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657–663. DOI: 10.1016/S0140-6736(09)61963-2
Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430–434. DOI: 10.1055/s-0037-1615600
Yuhara H, Steinmaus C, Corley D et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:953–962. DOI: 10.1111/apt.12294
Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272–2280. DOI: 10.1111/j.1572-0241.2008.02052.x
Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014;146:835-848.e6. DOI: 10.1053/j.gastro.2014.01.042
Sinh P, Cross R. Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease. Inflamm Bowel Dis 2021;27:1107–1115. 10.1093/ibd/izaa258. DOI: 10.1093/ibd/izaa258
Bunu D-M, Timofte C-E, Ciocoiu M et al. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract 2019;2019:3012509. DOI: 10.1155/2019/3012509
Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382-393.e1. DOI: 10.1016/j.cgh.2013.08.023
Dagli N, Poyrazoglu OK, Dagli AF et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology 2010;61:198–204. DOI: 10.1177/0003319709333869
Biondi RB, Salmazo PS, Bazan SGZ et al. Cardiovascular risk in individuals with inflammatory bowel disease. Clin Exp Gastroenterol 2020;13:107–113. DOI: 10.2147/CEG.S243478
Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010;121:2146–2150. DOI: 10.1161/CIRCULATIONAHA.110.951236
Sun H-H, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol 2018;25:1623–1631. DOI: 10.1177/2047487318792952
Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007;102:662–667. DOI: 10.1111/j.1572-0241.2006.01018.x
Duricova D, Pedersen N, Elkjaer M et al. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347–353. DOI: 10.1002/ibd.21007
Jess T, Gamborg M, Munkholm P, Sørensen TIA. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007;102:609–617. DOI: 10.1111/j.1572-0241.2006.01000.x
Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–1736. DOI: 10.1056/NEJMoa1606910
European Medicines Agency. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Published online March 20, 2019.
Giménez Poderós T, Gallardo Borge S, Vazquez-Ferreiro P. Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta-analysis. Pharmacotherapy 2020;40:1248–1264. DOI: 10.1002/phar.2472
European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. European Medicines Agency. Accessed March 2021. https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz.
The U.S. Food and Drug Administration. Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication: Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine. FDA. Accessed March 2021. https://www.fda.gov/safety/medical-product-safety-information/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-initial-safety-trial-results-find-increased.
Piepoli MF, Hoes AW, Agewall S et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the european association for cardiovascular prevention and rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381. DOI: 10.1093/eurheartj/ehw106
Konstantinides SV, Meyer G, Becattini C et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603. DOI: 10.1093/eurheartj/ehz405
Emanuel G, Charlton J, Ashworth M et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care. Heart Br Card Soc 2016;102:1957–1962.
Aarestrup J, Jess T, Kobylecki CJ et al. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. J Crohns Colitis 2019;13:319–323. DOI: 10.1093/ecco-jcc/jjy164
Kirchgesner J, Beaugerie L, Carrat F et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut 2018;67:1261–1268. DOI: 10.1136/gutjnl-2017-314015
Kirchgesner J, Nyboe Andersen N, Carrat F et al. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut 2020;69:852–858. DOI: 10.1136/gutjnl-2019-318932
Gill GS, Fernandez SJ, Malhotra N et al. Major acute cardiovascular events in patients with inflammatory bowel disease. Coron Artery Dis 2021;32:73–77. DOI: 10.1097/MCA.0000000000000899
Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol 2020;26:1231–1241. DOI: 10.3748/wjg.v26.i12.1231
McKie K, McLoughlin RJ, Hirsh MP et al. Risk factors for venous thromboembolism in children and young adults with inflammatory bowel disease. J Surg Res 2019;243:173–179. DOI: 10.1016/j.jss.2019.04.087
McCurdy JD, Kuenzig ME, Smith G et al. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2020;26:1761–1768. DOI: 10.1093/ibd/izaa002
Andrade AR, Barros LL, Azevedo MFC et al. Risk of thrombosis and mortality in inflammatory bowel disease. Clin Transl Gastroenterol 2018;9:142. DOI: 10.1038/s41424-018-0013-8
Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA) | Pfizer. Accessed March 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing.
Sandborn WJ, Panés J, Sands BE et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 2019;50:1068–1076. DOI: 10.1111/apt.15514
Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. In Press.
